Celebrity Inventors
Walt Disney was no Mickey Mouse inventor. He devised a serious animation camera which he patented. With the device, his company created "Snow White".
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8168753 | Thrombin cleavable factor X analogues The invention relates to factor X analogues containing the thrombin-cleavable sequence Pro-Arg-Ala in place of the-sequence Thr-Arg-Ile of the activation site of native factor X. These factor X analogues can be used to obtain procoagulant medicinal products. ... | 05/01/2012 |
| 8124736 | Alpha-1-antitrypsin compositions A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a re... | 02/28/2012 |
| 8063185 | Refolded recombinant β-secretase crystals and methods for preparing and using the same The present application relates to methods for growing crystals of both the uncomplexed and complexed forms of β-secretase (BACE) polypeptide. The present application also relates to crystalline forms of uncomplexed BACE and the three-dimensional structure of BACE,... | 11/22/2011 |
| 8048990 | Modified vitamin K-dependent polypeptides The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described. ... | 11/01/2011 |
| 7863420 | Process for removing fibronectin from plasma fractions The invention relates to a method for separating fibronectin from plasma fractions by adjusting a pH value of less than 5.4 such that fibronectin is precipitated and extracted from the solution. ... | 01/04/2011 |
| 7777006 | Method for purification of alpha-1-antitrypsin A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a re... | 08/17/2010 |
| 7718773 | Phosphate-binding protein, pharmaceutical compositions containing same and use thereof A protein includes or is formed by: (i) SEQ ID NO: 1; (ii) any sequence that is derived from sequence SEQ ID NO: 1, for example, by the substitution, removal or addition of one or more amino acids, on the condition that the derivative sequence binds to the phosphate... | 05/18/2010 |
| 7696318 | Host cell protein knock-out cells for production of therapeutic proteins The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants ... | 04/13/2010 |
| 7659373 | Erythropoietin with high specific activity The invention concerns new EPO compositions with high specific activity which are characterized by a high proportion of N-acetyl-lactosamine units or/and tetraantennary branches in the carbohydrate structure. In addition the invention concerns a process for producin... | 02/09/2010 |
| 7605232 | Hydrogels for protein concentration A method of concentrating proteins from whole blood comprising exposing whole blood to covalently crosslinked hydrogel to remove water from the blood into the hydrogel to thereby concentrate the proteins in the whole blood. The hydrogel may absorb, for example, 50% ... | 10/20/2009 |
| 7557188 | Methods of treating blood coagulation disorders using a pharmaceutical preparation comprising vWF propeptide Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWF propeptide as well as a method for producing such a preparation. ... | 07/07/2009 |
| 7425616 | Use of C-reactive protein to treat immune complex-mediated renal disease The present invention relates to a method of treating or preventing kidney disease in an animal subject including administering an effective amount of C-reactive protein to the animal subject. The kidney disease may be associated with systemic lupus erythematosus. | 09/16/2008 |
| 7390488 | Compositions and methods for producing vascular occlusion The present invention relates generally to methods and compositions for targeting, delivering, and activating platelet-dependent vascular occlusion agents. In particular, antibodies carrying platelet binding agents are targeted to hyperplastic cells or tissues, such... | 06/24/2008 |
| 7378393 | Recombinant anticoagulant proteins Novel recombinant anticoagulation proteins, methods of their use and methods of their production are described. In particular, recombinant fusions of annexin V (ANV) and Kunitz protease inhibitors (KPI) that possess potent anticoagulant activity are provided. The fu... | 05/27/2008 |
| 7358337 | Assay for low molecular weight heparin A prothrombin time reagent for determination of low molecular weight heparin in frsh whole blood and in anti-coagulant treated blood is provided. The reagent is composed of recombinant animal tissue factor, and a mixture of synthetic phospholipids, which mixture inc... | 04/15/2008 |
| 7354905 | Prodrugs of thrombin inhibitors There is provided compounds of formula I, R1O(O)C—CH2—(R)Cgl-Aze-Pab-R2I wherein R1 and R2 have meanings given in the description, which are useful as prodrugs of inhibitors of trypsin-li... | 04/08/2008 |
| 7351561 | Thrombin preparations and process for their production The production of a thrombin preparation which is obtained from prothrombin which is, after activation to thrombin without the addition of thromboplastin, purified by a hydrophobic interaction chromatography, it being possible subsequently also to inactivate or remo... | 04/01/2008 |
| 7351524 | Diagnostics and therapeutics for macular degeneration-related disorders The invention relates to methods for treating, preventing and diagnosing macular degeneration-related disorders. ... | 04/01/2008 |
| 7348411 | Process for manufacturing fibrin membranes and fibrin membranes obtained according to this process A process for manufacturing a fibrin membrane from blood plasma that was partially depleted and subjected to coagulation by adding a solution of a physiological coagulating agent, leaving the mixture to stay until forming a gelatinous blood clot, and then dehydratin... | 03/25/2008 |
| 7335467 | Breast cancer antigens The invention provides methods for diagnosing cancer including breast cancer, based on the identification of certain breast cancer-associated polypeptides as antigens that elicit immune responses in breast cancer. The identified antigens can be utilized as markers f... | 02/26/2008 |
| 7332577 | Therapeutic human albumin solutions with low prekallikrein activator (PKA) activity and process for obtaining them The invention discloses a purified albumin solution of human origin with low prekallicrein activator (PKA) activity and stability over time characterised in that it has an antithrombin content equal to or greater than 0.03 mg/g of albumin, and a process for producti... | 02/19/2008 |
| 7320962 | Hemoactive compositions and methods for their manufacture and use Dried hemoactive materials comprise both a cross-linked biologically compatible polymer and a non-cross-linked biologically compatible polymer. The cross-linked polymer is selected to form a hydrogel when exposed to blood. The non-cross-linked polymer is chosen to s... | 01/22/2008 |
| 7314917 | Modified vitamin K-dependent polypeptides The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described. ... | 01/01/2008 |
| 7309774 | Antiplasmin cleaving enzyme Human α2-antiplasmin (α2AP) is the major inhibitor of the proteolytic enzyme plasmin that digests fibrin. Two forms of α2AP circulate in human plasma: a 464-residue protein, which we have termed “pro”-form, or α2AP... | 12/18/2007 |
| 7297680 | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content Disclosed are immortalized human embryonic retina cells, having a nucleic acid sequence encoding an adenoviral E1A protein integrated into the genome of the cells, and further comprising a nucleic acid sequence encoding an enzyme involved in post-translational modif... | 11/20/2007 |
| 7294699 | Modified vitamin K-dependent polypeptides The invention provides vitamin k-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described. ... | 11/13/2007 |
| 7288257 | Diagnosis and treatment of human dormancy syndrome New methods for diagnosis of human dormancy syndrome are provided. Human dormancy syndrome is characterized by elevated serum ratio of rT3/fT3 compared to a population of normal subjects from which subjects suffering from fibromyalgia, chronic fatigue, obesity, deme... | 10/30/2007 |
| 7288253 | Antibodies directed to parathyroid hormone (PTH) and uses thereof Embodiments of the invention described herein relate to antibodies directed to the antigen parathyroid hormone (PTH) and uses of such antibodies. In particular, in some embodiments, there are provided fully human monoclonal antibodies directed to the antigen PTH. In... | 10/30/2007 |
| 7285418 | Method and kit for the diagnosis of troponin I The invention provides a method for assaying for troponin I in a sample such as serum, the method comprising a determination of the troponin I concentration in a sample using a standard preparation that comprises a complete native troponin complex. One exemplary ass... | 10/23/2007 |
| 7282567 | Monoclonal antibody hPAM4 This invention relates to monovalent and multivalent, monospecific antibodies and to multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope o... | 10/16/2007 |
| 7268110 | Agents for preventing and treating thrombocytopenia Method of increasing blood platelet formation by administering a parathyroid hormone (PTH) or at least one PTH derivative as an active ingredient. ... | 09/11/2007 |
| 7265205 | Monomeric streptavidin muteins The invention includes a streptavidin mutein having at least one mutation chosen to cause one or more of steric hindrance, charge repulsion, or improvement of solubility by changing interfacial hydrophobic residues to less hydrophobic or hydrophilic residues. The mu... | 09/04/2007 |
| 7264805 | Proteins with a high immunoreactivity and a method for the production thereof The invention relates to (glyco-) proteins, in particular monoclonal antibodies, which have an immunoreactivity of >81%, preferably >90%. The inventive monoclonal antibodies are produced using a fluidized bed reactor in conjunction with a conventional protein-chemic... | 09/04/2007 |
| 7253142 | Protein solution preparation and method of stabilizing the same The present invention provides stable protein solution formulations filled in a container made from a hydrophobic resin at least for the part in direct contact with said formulation. ... | 08/07/2007 |
| 7252824 | Anti-neovasculature preparations for cancer Disclosed herein are immunogenic compositions, methods of designing immunogenic compositions, methods of treatment using immunogenic compositions, methods of evaluating cell-mediated immunity resulting from immunogenic compositions, research models, and methods of m... | 08/07/2007 |
| 7247708 | Modified vitamin K-dependent polypeptides The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described. ... | 07/24/2007 |
| 7247707 | Albumin-free factor VIII formulations A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent select... | 07/24/2007 |
| 7238786 | Monoclonal antibody cPAM4 This invention relates to monovalent and multivalent, monospecific antibodies and to monovalent and multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen ... | 07/03/2007 |
| 7235255 | Biological bioadhesive compositions and methods of preparation and use The present invention relates generally to the preparation and use of biological tissue adhesives which rely on combining fibrinogen and thrombin. More particularly, the present invention relates to a method of preparing a fibrin sealant whereby said sealant is form... | 06/26/2007 |
| 7232888 | Antibodies against tumor surface antigens The present invention relates to improved antibodies against tumor surface antigens and their use in the treatment of tumors. Of particular interest are highly stable, humanized, high affinity antibodies against carcinoembryonic antigen (CEA), especially the antibod... | 06/19/2007 |
